anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Despite the common occurrence of cetuximab (Cmab)-induced skin toxicity, management strategies are not well established. The traditional mainstay method consists of topical steroids, which, if used excessively, may give rise to other concerns. Alternatively, adapalene can activate epidermal growth factor receptor pathways to potentially alleviate these toxicities.
METHODS: We prospectively studied 31 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who were eligible to use adapalene gel as a reactive treatment for topical steroid-refractory skin toxicity. For comparison, we retrospectively reviewed 99 patients with R/M SCCHN (historical control cohort) whose skin toxicity was mainly treated with topical steroids. We compared the frequency and severity of Cmab-induced skin toxicity, Cmab therapy status (e.g., dose modification), side effects caused by topical steroids and adapalene gel itself, and other medical interventions.
RESULTS: Adapalene gel was used by eight patients (25.8%) in the prospective cohort. Patients in the historical control cohort more frequently required escalation of topical steroid potency (34.3% vs. 12.9%, p = 0.022). Although there was no statistically significant difference in the frequency of grade ≥3 facial skin rash and paronychia between the two cohorts, the prospective cohort showed a significantly shorter time to complete recovery from grade 2/3 paronychia (16 vs. 47 days, p = 0.017). Further, while no skin infections were observed in the prospective cohort, 13 patients in the historical control cohort developed skin infections, especially periungual infection (0% vs. 13.1%, p = 0.024). In addition, no patients in the prospective cohort received a dose reduction of Cmab due to skin toxicities, compared to 20 patients in the historical control cohort (0% vs. 20.2%, p = 0.003). No apparent adapalene gel-related side effects were observed.
CONCLUSIONS: Adapalene gel may be an effective management option for topical steroid-refractory Cmab-induced skin toxicities and could improve compliance with Cmab therapy.
The present invention relates to a traditional Chinese medicine composition for the treatment of white lesions of the vulva, which takes more than 10 Chinese herbal medicines of raw coix seed, flastem milkvetch seed, common cnidium fruit, epimedium herb etc. as the raw materials. The present invention has the effects of nourishing liver and kidney, eliminating dampness and eliminating spots. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition for the treatment of white lesions of the valva. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and its incidence is increasing worldwide.Resection of the primary ICC tumor site within the liver represents the best curative treatment option. However, the role of lymphadenectomy (LND) at the time of surgery remains controversial with some centers considering it standard while other surgeons perform LND only in select circumstances. The utilization of LND may not only vary among different institutions, but also by geographic region. Specifically, data from East and West centers have noted a variation in the utilization of LND ranging 27%-100%.While several case series from Asia have noted that most centers do not regularly perform LND,other data from the West suggest that LND may be becoming more routine. Despite the lack of consensus among surgeons, the American Joint Committee on Cancer (AJCC) Staging manual recommends that the nodal basin be staged. Disease-specific staging for ICC was first introduced in the 7th edition of the AJCC staging manual published in 2010. The newly updated 8th edition of the AJCC staging system now recommends that 6 lymph nodes be evaluated to stage a patient with ICC.

The previous multi-institutional retrospective study from the investigators have showed an increasing adoption of LND among patients undergoing curative resection for ICC during the last decade. The current prospective and randomized study based on a multi-institutional collaboration would investigate whether routine LND would benefit patients in short- and long-term survival remains.
The Human Leukocyte Antigen (HLA) system contains a set of genes involved at many levels in the innate and adaptive immune response. Among the non-classical HLA class I genes, HLA-G stands out for the numerous studies about its pivotal role in regulating/modulating immune responses. Also, its involvement in extravillous cytotrophoblast function, viral infections, autoimmunity, and cancer has been extensively documented. The present study explores for the first time the relationship between natural alleles of HLA-G, rather than STSs, SNPs, or partial gene polymorphisms, and the development of gastric adenocarcinoma, by analyzing the genetic profile of a cohort of 40 Spanish patients with this type of tumor using DNA extracted from paired biopsies of tumoral and adjacent non-tumoral gastric tissue. Our results reveal a significant statistical relationship between the presence of the HLA-G*01:01:01 allele and the development of gastric cancer, while other common alleles such as -G*01:04 or -G*01:05N did not demonstrate a significant correlation. Studying the involvement of HLA genes in the development of many diseases is relevant to understanding their pathophysiology. However, the absence of specific mechanisms underlying these associations suggests that investigating complete HLA natural alleles' extended haplotypes or complotypes may offer a more precise and valuable approach to elucidating the association of HLA with the pathogenesis of disease.
Allopurinol has the following structural formula:

Allopurinol is known chemically as 1,5-dihydro-4 H-pyrazolo [3,4- d]pyrimidin-4-one. It is a xanthine oxidase inhibitor which is administered orally. Each scored white tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. Each scored orange tablet contains 300 mg allopurinol and the inactive ingredients colloidal silicon dioxide, FD&C Yellow No. 6 Lake, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. Its solubility in water at 37°C is 80 mg/dL and is greater in an alkaline solution.
<P>PROBLEM TO BE SOLVED: To allow a plurality of doctors to efficiently carry out diagnosis cooperatively.  <P>SOLUTION: A client hospital 1 such as an examination center is provided with a photographing device such as a retinal camera 2 and a client doctor terminal 3 for making a request of another doctor or a diagnostician. A database 4 in the client hospital 1 is connected to the retinal camera 2 and the client doctor terminal 3. The client doctor terminal 3 is connected to a management server 5 via a network such as a LAN and the Internet. To the management server 5, diagnostician terminals 6A, 6B, and 6C toward remote diagnosticians A, B, and C are connected to be connected to introduced doctor terminals 7D and 7E toward introduced doctors D and E. The diagnosticians A, D, C make diagnoses based on data transmitted from the client doctor terminals 3 via the management server 5, and if secondary diagnosis is necessary, notify necessity of the secondary diagnosis. The management server 5 introduces the introduced doctors D and E for asking the secondary diagnosis, and then, performs money distribution and billing for payment to the diagnosticians and the introduced doctors and an introduction fee.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention discloses an oxytropis ehrig verticillium FEL5-AS1 of a synthesized swainsonine which is preserved in China Center for Type Culture Collection on 8th, Oct of 2008, with the preservation number of CCTCC NO: M 2008144. The colony of the bacterial strain is round, which is white at first. With the extension of the culturing time, the colony gradually changes into straw yellow, tan and pitchy, and the center processes a little. Mycelium has transverse layers but has no mediastinum. Part of aged mycelia produces conidiophores which have branches. The conidiophores bend like knee bending, and spore formation scars are obvious. Conidia and conidiophores have transverse layers but have no mediastinum. The diaphragm of the conidia is thick, and the transverse layers consist 1-4. The spores are bar-shaped, similar to column. The size of the conidia is 20-90Mum multiplied by 5-10 Mum. The bacterial strain is obtained from leaves, stems and seeds of astragalus strictus by artificialseparation and screening and has the function of synthesizing swainsonine (SW) which is main toxin of locoweed.
This study is a multi-center, prospective, international, Phase III, randomized and blinded investigation of 6 weeks versus 6 months of oral valganciclovir therapy in babies with symptomatic congenital cytomegalovirus (CMV) disease. Following enrollment, study subjects will receive 6 weeks of oral valganciclovir. Near the end of the 6-week course, subjects will be randomized in a 1:1 fashion either to continue on valganciclovir to complete 6 months of therapy or to begin a matching placebo to complete the 6 months. Study subjects will be stratified according to whether or not there is central nervous system (CNS) involvement at study entry. During the 6-month treatment period and the 1 month thereafter, study subjects will be followed weekly for 4 weeks, then every other week for 8 weeks, then every month for 4 months. At each of these visits, safety labs will be checked, growth parameters recorded, and adverse events assessed. The dose of study medication will be adjusted for weight gain at each of these study visits. Dose adjustments may also occur as indicated per protocol for neutropenia, thrombocytopenia, or renal impairment. Whole blood will be obtained for CMV viral load at each of these visits as well. Hearing outcomes will be assessed at baseline, 6 months, 12 months and 24 months. Developmental outcomes will be assessed at 12 months and 24 months. Changes in whole blood viral load measurements will be correlated with both hearing and neurologic outcomes. In study subjects with increasing whole blood viral loads during the course of treatment, assessment for antiviral resistance may be undertaken.Safety assessments include: hematology labs, chemistry labs, physical examinations, and adverse event data performed/collected serially. Development of neutropenia will be confirmed by repeat blood testing within one week, and study drug will be held until it resolves. Efficacy assessments include: hearing assessments at baseline, 6 months, 12 months and 24 months; and neurodevelopmental assessments at 12 months and 24 months. Study objectives are: to compare the impact on hearing outcomes of 6 weeks versus 6 months of antiviral treatment with valganciclovir oral solution in infants with symptomatic congenital CMV disease; to compare the safety profile of 6 weeks versus 6 months of antiviral therapy with valganciclovir oral solution in infants with symptomatic congenital CMV disease; to compare the impact on neurologic outcomes of 6 weeks versus 6 months of antiviral treatment with valganciclovir oral solution in infants with symptomatic congenital CMV disease; and to correlate change in whole blood viral load with hearing and neurologic outcomes. Participants will include 104 male and female neonates (less than or equal to 30 days) with symptomatic congenital CMV.
Patients will be treated with bezlotoxumab at a dose of 10mg per kg of body weight (up to maximum of 1000mg) dissolved in 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
In addition to the standard wound care procedure, the Virtual Reality Therapy group (intervention group 1) will receive the VR system during the wound care. The VR system consists of Virtual Reality glasses, a controller and a headphone. The application SyncVR Relax \& Distract will be used, which will contain various videos for the patient those from to relax and be distracted. This group wears the VR system 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment in Peking University Third Hospital. Radioactive Iodine-125 seed brachytherapy is the implantation of Iodine-125 seed into tumors.The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. 3D-printing non co-planar template is made individually which guides the implantation of Iodine-125 seed into the tumor and ensures the accuracy of the position.This study collects the data of patients with pelvic recurrent rectal carcinoma who underwent 3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed implantation from 2015 to 2018. We evaluate the dose that covers 90% target volume(D90),the volume that 100% prescription dose covers(V100) and other dosimetric parameters after the implantation. The efficacy and adverse effects were observed. Local control(LC) time and overall survival(OS) time are evaluated.
Alzheimer's disease is a progressive neurological disorder causing memory loss and cognitive decline. The underlying causes of cognitive deterioration and neurodegeneration remain unclear, leading to a lack of effective strategies to prevent dementia. Recent evidence highlights the role of neuroinflammation, particularly involving microglia, in Alzheimer's disease onset and progression. Characterizing the initial phase of Alzheimer's disease can lead to the discovery of new biomarkers and therapeutic targets, facilitating timely interventions for effective treatments. We used the AppNL-G-F knock-in mouse model, which resembles the amyloid pathology and neuroinflammatory characteristics of Alzheimer's disease, to investigate the transition from a pre-plaque to an early plaque stage with a combined functional and molecular approach. Our experiments show a progressive decrease in the power of cognition-relevant hippocampal gamma oscillations during the early stage of amyloid pathology, together with a modification of fast-spiking interneuron intrinsic properties and postsynaptic input. Consistently, transcriptomic analyses revealed that these effects are accompanied by changes in synaptic function-associated pathways. Concurrently, homeostasis- and inflammatory-related microglia signature genes were downregulated. Moreover, we found a decrease in Iba1-positive microglia in the hippocampus that correlates with plaque aggregation and neuronal dysfunction. Collectively, these findings support the hypothesis that microglia play a protective role during the early stages of amyloid pathology by preventing plaque aggregation, supporting neuronal homeostasis, and overall preserving the oscillatory network's functionality. These results suggest that the early alteration of microglia dynamics could be a pivotal event in the progression of Alzheimer's disease, potentially triggering plaque deposition, impairment of fast-spiking interneurons, and the breakdown of the oscillatory circuitry in the hippocampus.
The invention comprises 2-R-4-R1-6-R11-pyrazolo[3,4-d]pyrimidines, their tautomers and their addition salts with inorganic or organic acids (including ascorbic, salicyclic and p-aminosalicyclic acids, methionine, tryptophane, lysine and arginine), in which R represents a C1-6 aliphatic hydrocarbon radical, R1 a halogen atom, an alkoxy or alkyl-mercapto group (the alkyl groups containing 1-6 carbon atoms) or a free mercapto or amino group or an amino group substituted by a C1-6 aliphatic hydrocarbon, or an oxa- or aza-alkylene radical, and R11 has the same meaning as R1 or represents a hydrogen atom or a C1-6 alkyl group and 2 - R - 4 - R1 - 6 - R11 - pyrazolo [3,4 - d] pyrimidines in which R represents a C1-6 aliphatic hydrocarbon radical, R1 a free hydroxyl group and R11 for a free hydroxyl group or for a hydrogen atom or a C1-6 alkyl group.  The compounds may be substituted in the 3-position by an alkyl or aryl radical and also in the 5 and/or in the 7-position by alkyl radicals provided that there is a thiono group in the 4- or the 6- position.  The compounds of the invention may be prepared by reacting 1 - R - 3 - amino - pyrazole-4-carboxylic acids with carboxylic acids in the form of their functional derivatives or of the feee acids, provided that in the reactants at least one of the two carboxyl groups contain an amino group suitable for ring closure and in the resulting 4- and/or 6-hydroxy[3,4-d]pyrimidines having free hydroxyl groups the free hydroxyl groups are replaced by halogen atoms, alkoxy, alkylmercapto, free mercapto, free amino or substituted amino groups and/or, if desired, free or alkylated mercapto groups are replaced by free or substituted amino groups by methods known per se.  For reaction with amino-pyrazoles there are used functional derivatives of formic acid, e.g. formamide; carbonic acid, e.g. urea, thiourea, guanidine, halogen carbonic acid esters, carbonic acid dihalides, e.g. phosgene, cyanates and iso-cyanates, thiocyanates and isothiocyanates; or lower fatty acids in the form of their anhydride, esters or halides.  In in the case of carboxylic acid derivatives free from nitrogen there are used pyrazole-4-carboxylic acids in the form of their acid derivatives containing nitrogen, such as the amide.  The above compounds, which have diuretic coronary dilating, tumor-inhibiting, antibacterial antimycotic and caffeine-like effects, may be used in pharmaceutical compositions comprising the active ingredient and a carrier therefor.  The compositions may be in a form suitable for topical, enteral or parenteral administration, e.g. tablets, dragees, solutions, suspensions or emulsions.  Specifications 835,918 and 884,851 are referred to.
The computer-implemented system of providing online medical consultation services by a team of medical professionals begins when a user accesses the system website. The user selects the level of consultation services desired and a case submission form is provided to the user requesting information relating to desired medical consultation. The user provides the requested information on case submission form. If additional information is required, it is obtained. When the case is ready for submission, members of the medical professional team are selected for consultation on the case and forwarded the particulars of the submitted case via the Internet. The selected team members review the submitted case particulars and each member provides their medical opinion via Internet. The submitted opinions are recorded and displayed in real time on the system website, to which the user has access. In addition, the submitted opinions to structured questions are compiled to determine if there is a consensus. A graphical representation of the compiled opinions is generated and displayed in real time on the website, as well. This system can provide nearly instant information as to the sum of the opinions of medical experts for a variety of case scenarios and establishes whether, and to what extent, a consensus exists among the consulting medical professionals.
Obesity is recognized as a significant contributor to the onset of kidney disease. However, the key processes involved in the development of kidney disease in obese individuals are not well understood. Here, we investigated the effects of high-fat diet (HFD)-induced obesity on folic acid (FA)-induced kidney injury in mice. Mice were fed an HFD for 12 weeks to induce obesity, followed by an additional intraperitoneal injection of FA. The results showed that mice fed HFD developed higher levels of kidney damage than those in the chow group. In contrast, mice exposed to both HFD and FA showed less fibrosis and inflammatory responses compared to the FA only treated group. Furthermore, the HFD with FA group exhibited elevated lipid accumulation in the kidney and reduced expression of mitochondrial proteins compared to the FA-treated group. Under in vitro experimental conditions, we found that lipid accumulation induced by oleic acid treatment reduced inflammatory and fibrotic responses in both renal tubules and fibroblasts. Finally, RNA sequencing analysis revealed that the inflammasome and pyroptosis signaling pathways were significantly increased in the HFD group with FA injection. In summary, these findings suggest that obesity increases renal injury due to a lack of appropriate inflammatory, fibrotic, and metabolic responses and the activation of the inflammasome and pyroptosis signaling pathways.
To compare the efficacy of transconjunctival needling revision (TNR) with 5-fluorouracil versus medical treatment (MT) in glaucomatous eyes with uncontrolled intraocular pressure (IOP) due to encapsulated bleb after trabeculectomy Prospective, randomized, interventional study. A total of forty eyes of 39 patients with elevated IOP and encapsulated bleb diagnosed at maximum 5 months after primary trabeculectomy with mitomycin C were included. The eyes were randomized to either TNR with 5-fluorouracil or MT (hypotensive eyedrops). A maximum of two TNR per patient was allowed in the needling arm. All eyes were followed up for 12 months. Success of treatment was defined as IOP ≤ 18mmHg and 20% reduction from baseline at last follow up.
Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.

The dose escalation phase has completed for apatinib from 125mg, 250mg to 500mg. The dose of 250mg showed best tolerance and efficacy especially in hepatocellular carcinoma. Thus, for hepatocellular carcinoma patients, apatinib 250mg orally every day was chosed for the dose extension phase. In gastric cancer, the dose of 250mg also showed good tolerance but mild efficacy. Thus, for gastric cancer patients, the dose of 375mg daily for apatinib would be explored and then the investigators will decide the best dosage for these patients.
Participants in the intervention group engage in a 10-week program that includes both drumming and dancing sessions. The group is further divided into two subgroups due to logistical reasons, with one subgroup attending five weeks of drumming sessions followed by five weeks of dancing sessions, and the other subgroup attending sessions in the opposite order. All participants in this arm participate in both drumming and dancing sessions.
PURPOSE:To prepare radioactive hot bath, from a trace of disintegrated products of a radioactive substance, by extracting a radioactive natural mineral or a radioactive compound with an aqueous solution of an organic acid. CONSTITUTION:A radioactive natural mineral [e.g. monazite: (ce, La, Y, Th) PO4], or a radioactive compound is immersed in an aqueous solution of an organic  acid (e.g. succinic acid), if necessary, with stirring. A trace of disintegrated product is extracted with the solution, which is then diluted with a proper amount of  hot water or cold water to obtain the radioactive hot bath, especially artificial radium bath. The extraction is pref. carried out at about 100 deg.C.